Our Team

We are career venture capitalists, biotech founders, former pharma and biotech executives, research scientists, medical doctors, and experienced drug developers. What unites us is the passion for biotech start-ups, innovation and the quest for new and better medicines.

Dr. Klaus Breiner

Managing Partner

Managing Partner at BB Biotech Ventures since 2004. Co-founder and, from 2008 till 2016, Executive Chairman of Vaximm. Prior to joining Bellevue, Investment Manager at GLS Ventures in Munich. He has invested in a number of bio-pharmaceutical companies, such as Glycart, Intercell, Pevion, Vaximm and AM-Pharma. PhD Molecular Biologist & Chemist.

Dr. Dominik Escher

Managing Partner

Former Founder & CEO of ESBATech, a Swiss biotech focusing on next generation antibody drugs. Alcon acquired ESBATech for USD 589 mn in 2009. Subsequently until 2016 Vice President of Alcon R&D. Member of the Global Ophthalmology Leadership and Global Biologics Leadership of Novartis Institutes of Biomedical Research. Since 2002 on the Board of the Swiss Biotech Association.

Dr. Martin Münchbach

Managing Partner

Managing Partner at BB Biotech Ventures since 2004. Prior to joining Bellevue Group, Investment Manager at BioMed, HBM and NMT. Martin’s past and current board assignments include Bellevue’s most successful private biopharmaceutical investments, such as Radius Health, Molecular Partners, Optimer Pharmaceuticals, Axovan and Glycart. PhD Protein Chemist & Biochemist.

Dr. Ximing Ding


Analyst at BB Puros Bioventures since 2018. PhD Molecular Biologist

Dr. Alexander Breidenbach

Entrepreneur in Residence

Dr. Michael Motz

Entrepreneur in Residence

Dr. Thomas Hecht

Advisory Board

Past and present Chairman or Director at several biopharmaceutical companies, including ESBATech, Cytos, Affimed, Cellmedica, Suppremol, Humabs, and Vaximm; senior veteran from Amgen Europe (Clinical, Med affairs & Marketing).

Prof. Dr. Roger Nitsch

Advisory Board

University of Zurich, key opinion leader in neurodegenerative diseases; directs the Institute for Regenerative Medicine; Co-founder and Chairman of Neurimmune, developer of aducanumab, now in partnership with Biogen (Alzheimer’s disease).

Prof. Dr. Bernd Seizinger

Advisory Board

Dr. Mathieu Simon

Advisory Board

Former EVP, COO and board director of Cellectis, a premier CAR T-cell and DNA editing company, NASDAQ listed (CLLS). Prior to that, Head of Global Pharmaceutical Operations at Pierre Fabre and in senior corporate and regional roles at Wyeth (US and Europe). Medical Doctor.

Dallas Webb

Advisory Board

Portfolio Manager at BB Biotech AG in New York since 2006, prior healthcare equity analyst positions with Stanford, Sterling, and Adam Harkness & Hill. Dallas holds an MBA and a BS in Microbiology.

Ben Morgan